Exicure, Inc.

The company, historically an early-stage biotechnology firm, focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, it significantly reduced its workforce, suspended preclinical activities, and halted all research and development. In February 2024, the company received an upfront payment of $500,000 from a licensing agreement for patents related to one of its historical drug candidates, along with a small, one-time payment and an entitlement to modest future royalties. In the second quarter of 2024, it recognized other income of $637,000 from the sale of samples related to the licensed product. In the third quarter of 2024, the company sold its historical biotechnology intellectual property and other assets, including the aforementioned licensing agreement, recognizing other income of $1,500,000. Any future value from these historical assets will primarily come from royalties and license fees under this purchase agreement, though these are uncertain. The company is actively exploring strategic alternatives, including private company acquisitions, raising additional capital, and strategic partnerships. On January 19, 2025, the company acquired all issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation, from GPCR Therapeutics Inc., a Korean corporation.